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medications and obstetric medical history. Set-up was non-random, convenience 
sampling with 40 women’s data with mean age 33.7± 3.6, between August 2013 – 
February 2014. Friedmann ANOVA and t-test was applied for analysis with software 
Statistics for Windows. Results: Progresses the gestation period significant reduc-
tion of TSH values was observed in hypothyroid patients (p= 0,0075). Comparing 
successive TSH values of the individual patients showed the same significant dif-
ference. Significant negative correlation was founded between TSH value and thy-
roxin dose in group of hypothyroid patients (r= -0,35; p< 0,05). Premature birth and 
other obstetric complications occured more frequently in the thyreotoxical group, 
especially among older women giving birth. ConClusions: In case of hypothyroid 
pregnant with increasing dose of thyroxin the TSH levels are well balanced, and 
obstetric complications did not occur, while in hyperthyroid patients can be reported 
obstetric complications in addition to proper care.
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objeCtives: Dapaglifozin is a highly potent, selective and reversible inhibitor of 
sodium-glucose co-transporter 2 (SGLT2) and is approved for the treatment of T2DM 
in adults. Diabetes type 2 is one of the most prevalent chronic diseases that can 
lead to serious complications and disability. The largest costs are those associated 
with hospitalizations due to the complications, the prevention of which requires a 
good glycemic control. The objective of the study is to estimate the budget impact 
of adding dapaglifozin to the therapy of type 2 diabetes in Bulgaria. Methods: The 
budget impact model was used from the payer perspective for population 7 284 552 
people, and out of them 450000 are type 2 diabetics. The retail pharmacy prices were 
used from the Positive Drug List. Official IMS data for antidiabetic medicines were 
incorporated in the model. Net budget impact is presented as costs per-member 
per-month (PMPM) and costs per-patient per-year (PPPY). Results: An increase in 
the estimated net budget impact from 70 592 € first year to 1 290 716 € for the fifth 
year was observed after adding dapaglifozin to T2DM therapy, with a cumulative 
net budget impact of 3 258 047 € . PMPM and PPPY costs show minimal growth with 
respective cumulative values of 0.06 € and of 65.63 € . The cost for dapaglifozin 
therapy is comparable to that of DPP-4 inhibitors and is lower than the cost of 
treatment with a GLP- 1. ConClusions: The results show that adding dapaglifozin 
to standard therapy will lead to minimal increase in the diabetes type 2 budget in 
Bulgaria. This increase is considered acceptable in terms of better glycemic control 
with safe and effective therapy for diabetes type 2.
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objeCtives: Objective of this study is to provide additional evidence for decision 
making to payers assessing health care resource utilization, economic impact, and 
cost-effectiveness of DPP-4 inhibitor alogliptin compared with sitagliptin, saxaglip-
tin and linagliptin, for the treatment of type-2 diabetes mellitus (T2DM). Methods: 
29 comparable, randomized clinical trials were selected out of a panel of 58 studies. 
6 different clinical endpoints (efficacy and safety) were compared across 5 different 
combinations: DPP-4 Monotherapy, +metformin (MET), +sulfonylurea (SU), +thia-
zolidinedione (TZD), +insulin (INS). For each endpoint and combination, aloglip-
tin clinical endpoints were compared with respective average endpoints of other 
DPP-4s. Differentials were calculated after adjustment for baseline characteristics. 
Each endpoint was associated with the impact on patient outcomes and related 
health care costs (T2DM-related complications, treatment escalation, costs associ-
ated with adverse events: hypoglycemia, cardiovascular mortality, hospitalization 
due to heart failure, lipids profile) obtained from published data. Economic value 
saving of alogliptin was calculated and compared to the other DPP-4s. Results: 
The proportion of patients at target (HbA1c< 7%) as well as the reduced need for 
treatment escalation with alogliptin could generate annual savings for a health care 
system of € 69.62 and € 22.97 per patient-year, respectively. Improved lipids profile 
and proven CV safety of alogliptin can generate savings of € 40.86 and € 21.47 per 
patient-year, respectively. Impact of lower hypoglycemia and increased adherence 
with fixed dose combinations with TZD may generate additional savings (€ 1.53 
and € 1.60/ patient-year, respectively). ConClusions: This study suggests that 
alogliptin could generate significant savings for a Healthcare System, even at price 
parity with other DPP-4s, thanks to its efficacy and safety profile, particularly in the 
widely used DPP-4+MET combination. Total savings of up to € 158 per patient-year 
compare favorably with an overall cost of treatment with a DPP-4i ranging from 
€ 350 to € 481 per patient-year.
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objeCtives: To conduct a cost-effectiveness assessment of glucose meters (manually 
coded and autocoded) in diabetes treatment in the Russian Federation. Methods: 
Clinical effectiveness assessment was based on the results of modeling of the treat-
ment of patients with diabetes that use manually coded and autocoded blood glucose 
meters. Cost analysis included assessment of direct and indirect costs that can be 
0.624 mg/dL for each additional (p= 0.017) year of age and triglycerides increased by 
1.417 mg/dL for each additional (p= 0.041) year of age. Changes in HbA1c, total cho-
lesterol and HDL-cholesterol over time were not significantly correlated with patient 
age or time since diagnosis. Therefore, health economic modelers may assume that 
these parameters remain stable over time. Sensitivity analyses were performed to 
address the potential mislabeling of T2DM as T1DM patients. ConClusions: These 
results provide relevant inputs for the progression of physiological parameters to 
model the economic and clinical impacts of T1DM therapies over time.
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objeCtives: To quantify the trend in prevalence and distribution of diabetes mel-
litus (DM) type I (T1DM) and type II (T2DM) in the Netherlands. Methods: Using 
the General Practitioner Database and the Out-patient Pharmacy Database of the 
PHARMO Database Network, the trend in prevalence of DM and distribution of 
T1DM and T2DM from 2005 to 2012 was assessed. Per year, patients with ≥ 2 anti-
diabetic drug dispensings within 6 months were selected as DM patient. Patient 
numbers were extrapolated to the Netherlands to determine prevalence of DM. 
For all patients, diabetes treatment at September 30 of that year was assessed. For 
patients with a GP recorded diagnosis for T1DM or T2DM, distribution of T1DM/T2DM 
was stratified by treatment. This distribution of DM type by treatment was applied 
to the treatment of patients with no GP recorded DM type to assess the distribution 
of T1DM/T2DM. Results: The prevalence of DM in the Netherlands increased from 
38 per 1000 males and 40 per 1000 females in 2005 to 54 per 1000 males and 52 per 
1000 females in 2012. The distribution of T1DM versus T2DM among patients with 
DM changed from 15% versus 85% in 2005 to 8% versus 92% in 2012. Among patients 
with T1DM mean (±SD) age decreased from 48 (±22) years in 2005 to 44 (±22) years 
in 2012. Among patients with T2DM mean age increased from 63 (±12) years in 2005 
to 67 (±12) years in 2012. ConClusions: This study describes the epidemiology of 
DM in the Netherlands over 2005-2012. Prevalence of DM increased and relatively 
more patients were diagnosed with T2DM. These changes can be explained by the 
ageing Dutch population, better survival, more obesity and early detection of T2DM. 
Furthermore, introduction of the T2DM care program in 2005 probably has led to a 
better registration of T2DM patients.
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objeCtives: HIPOS-ER is an observational, cross-sectional, multicenter study to 
describe the patient population of Type 2 diabetics treated with an anti-hypergly-
cemic agent (AHA) and admitted to the emergency room (ER) with a hypoglycemic 
event. In this analysis we aim to identify factors associated with hospitalization 
following admission in the ER. Methods: The study enrolled patients from 
7 centers in mainland Portugal for a period of 12 months (Jan 2013 – Jan 2014). 
Sociodemographic and clinical data were collected at the ER and patients who 
required hospital admission were followed up. Multiple logistic regression was 
used to identify factors associated with hospitalization. Results: A total of 238 
patients were enrolled of whom 105 (44%) were hospitalized. These patients were 
older than non-hospitalized (mean: 78 years vs. 75 years; p= 0.020). About half of 
the hospitalized patients were on secretagogue based regimen. Glasgow coma scale 
score was not statistically different between hospitalized and non-hospitalized 
patients (p= 0.270), however hospital admissions showed lower values of the lowest 
recorded plasma/capillary glycemia (mean: 35 mg/dL vs. 41 mg/dL; p= 0.004) and a 
higher prevalence of hypoglycemia complications (26% vs. 9%; p< 0.001). Obesity 
and higher plasma capillary glycaemia level are associated with a lower risk of 
hospitalization (OR= 0.29 and OR= 0.96, respectively; p< 0.010) while treatment with 
secretagogue based regimen, presence of hypoglycemia complications and other 
atherosclerotic disease are associated with a higher risk (OR= 5.71, OR= 3.89 and 
OR= 2.87, respectively; p< 0.010). ConClusions: Almost half of the patients with 
diabetes suffering a hypoglycemic event who required medical assistance at the ER 
were hospitalized. Presence of some factors may increase the risk of these expensive 
cases which are also surrogates for the potential severity of the hypoglycemic epi-
sodes. Identification of these predictors may help assist physicians at the emergency 
room to proactively act upon patients at higher risk of hospitalization and generate 
substantial health and economic gains to the hospitals.
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objeCtives: The most common endocrine clinical symptom is thyroid disease 
which has impact to pregnant women and fetus. Leading international refer-
ences about its treatments are well known, there is no relevant experiences in the 
Hungarian context. Aim of this study is to inspect the thyroid disease and impact 
of its treatment to outcome of pregnancy. Methods: Survey was carried out at 
Markusovszky Hospital in Vas County, Hungary. Retrospective study made by data 
analysis of pregnant patient with thyroid disease, including hormone parameters, 
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objeCtives: Smoking in diabetics is associated with a worse prognosis and vascular 
complications. The available evidence on health care resources utilization and associ-
ated costs in diabetics who smoke is limited or nonexistent. Thus, the objective was 
to compare health care resource utilization and costs according to smoking status in 
patients with type 2 diabetes in clinical practice. Methods: A retrospective cohort 
nested case-control study was designed. Cases were current smokers, while two types 
of controls (former smokers and never smokers) were matched, two controls per 
case, for age, sex, duration of diabetes, and burden of comorbidity using data from 
electronic medical records. Non-institutionalized diabetics, both genders, age > 18 
years, seen consecutively over a 5-year period before the index date were enrolled. 
Perspective of both the National Health System and the Society were chosen and costs 
of health care resource utilization and loss of productivity due to sick leaves were 
compared among groups using a linear general model with covariates. Results: A 
total of 2,490 records were analyzed: 498 from cases, 996 from former smokers, and 
996 from never smokers. Mean age was 63.4 years (64.9% male). Smokers had higher 
HbA1c (7.4% vs. 7.2% and 7.2%, respectively, p = 0.013) and a lower degree of metabolic 
control (49.2 % vs. 54.7% and 55.8%, p = 0.036). Smokers had higher average annual 
costs (€ 3,583) than former smokers (€ 2,885) and never smokers (€ 2,183), p< 0.001. Mean 
annual health care cost saving per patient was associated with elapsed time of quit-
ting smoking from € 950 in subjects quitting smoking 2-year to € 1173 5-year or more, 
p< 0.05. ConClusions: Diabetic smoker patients had lower metabolic control, higher 
health resource utilization, and more sick leave, resulting in higher health care costs 
and lost productivity compared with both former and never diabetic smokers. Health 
care cost-savings was associated with elapsed time from quitting smoking.
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objeCtives: The aim of this analysis was to estimate the potential GH waste per 
patient with pen devices and the easypod® device, and to quantify the potential 
economic impact of expected GH waste from patient and health care organization 
perspectives. Methods: A Waste Calculator Model was developed to examine GH 
waste. All somatropin products available in pen or electronic devices were included. 
The user may define distribution across cartridges sizes. The mechanical/priming 
loss applied to each product was based upon each product’s prescribing information 
and/or instructions for use. The base case model utilizes a US patient daily dose of 1.4 
mg. The model assumes that the easypod® dose adjustment feature is activated by 
the clinician (±25%). Model assumes that 42.6% of caregivers discard the remaining 
amount left in the cartridge (eg waste) if less than a full dose. Annual amount of GH 
waste (mg, cartridges, dollars) per patient and per population (based on US national 
market shares) for each pen/device is reported. Results: The expected annual 
amount of waste per patient was lowest for easypod®. The expected annual amount 
of waste per patient was highest for Omnitrope®. The expected annual amount of 
waste ranged from 0 to 38.9mg per patient per year, which is equal to 0 to 8 cartridges 
per patient per year and/or 0 to $2,935 per patient per year. For a patient population 
of 100 GH-treated patients, the annual amount of waste is estimated at 2,009 mg, 
which can be translated into approximately 342 cartridges or about $162,000 per year. 
The results in GH waste fluctuated depending upon daily dose, cartridge size, and 
dose spread assumptions. ConClusions: The expected annual amount of GH waste 
evaluated in this Waste Calculator was lowest with easypod®. Cost of GH waste can 
be an important consideration when evaluating GH delivery devices.
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objeCtives: It is estimated that the prevalence of moderate-to-severe SA (apnoea-
hypopnoea index > 15/h) is 10%. Patients with T2DM have a particularly high inci-
dence of SA. T2DM and SA influence the development and progression of each 
other. This study investigated the effects of PAP therapy in SA patients with T2DM 
on all-cause mortality and cost of illness (COI) in Germany from a statutory health 
insurance (SHI) perspective. Methods: A total of > 4 million individuals covered by 
the SHI database were analysed (≈5% of the German SHI population). PAP therapy 
was initiated in 4,068 patients with SA (PAP group). Propensity score matching 
was used to define a control group (CG) of 4,068 SA patients matched for age, sex, 
risk factors/aetiology, region and medication who received usual care (no PAP). Of 
these, 1,280 patients in the PAP group and 1,186 patients in the CG had comorbid 
T2DM. This subgroup of patients was followed for 3 years after initiation of PAP 
therapy. Results: Total COI was higher in the PAP group versus CG in year 1 (€ 8,105 
vs € 7,037, p< 0.0001). After 2 years’ follow-up, COI in the PAP group decreased but 
remained higher versus CG (€ 6,842 vs € 6,625, p< 0.001). After 3 years, PAP group COI 
associated with manually coded meters (model 1 and model 2) and autocoded meters 
(model 3). Cost data was based on median prices for medicines, devices, medical 
services in National health care system in the Russian Federation. Results: Annual 
direct costs per patient in the group of manually coded glucose meters were 1533 euro 
(model 1) and 1574 euro (model 2), and in the group of autocoded meters were 1557 
euro (model 3). Annual total costs per patient in the group of manually coded glucose 
meters were 2992 euro (model 1) and 2921 euro (model 2), and in the group of auto-
coded meters were 3034 euro (model 3). Cost-effectiveness ratio for autocoded meters 
was 1875 euro (model 3) and for manually coded meters was 1954 euro (model 1) and 
1982 euro (model 2) per 1 LYG, respectively (discounted at 3%). Budget impact analysis 
showed that use of autocoded meters (model 3) instead of manually coded (model 
1 and model 2) leads to the annually cost savings of 33 euro and 53 euro per patient, 
respectively (discounted at 3%). ConClusions: Obtained results approve the use of 
autocoded blood glucose meters instead of manually coded blood glucose meters to 
administrate blood glucose level as part of intensive glucose-lowering therapy from 
a pharmacoeconomic point of view.
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objeCtives: The costs of obesity are staggering, accounting for 2-6% of global 
health care costs. The health economic benefits of bariatric surgery while notable, 
are multi-faceted, resulting in heterogeneous reporting in the literature. To that 
end, this study seeks to 1) highlight available evidence of the health economic 
impact of bariatric surgery, and to 2) identify key gaps in current evidence that 
may influence uptake by health care systems. Methods: Evidence of the health 
economic impact was collated from 107 scientific articles, of which 19 were sys-
tematic reviews, published between 2010-March 2014 and archived in MEDLINE and 
PubMed. Additionally, HTAWatch identified 10 HTAs, largely from North America 
and the EU that evaluated economic benefits. Results: In all countries where 
evaluated, bariatric surgery was cost-effective compared to non-surgical therapy. 
The surgery was likely more cost-effective with higher patient BMI and with comor-
bidities, especially for BMI> 40kg/m2, although estimates varied. Furthermore, 
resolution of underlying comorbidities resulted in reduced utilization of health 
care services, pharmaceutical utilization, and improved work productivity, among 
others, resulting in cost saving of 60-70% relative to standard care over a 3-year 
period. Importantly, time to break even was typically in the 4-7 years range, and 
was shorter for patients with Type 2 Diabetes Mellitus (T2DM) and with BMI> 40kg/
m2, typically in the 1.25-5 year range. Three key evidence gaps were identified: few 
studies computed long-term cost-effectiveness; no head-to-head trials have directly 
compared different surgical procedures; and heterogeneity across populations and 
health system impede meta-analyses of patient outcomes such as QoL and long-
term health benefits. ConClusions: Although heterogeneous, reports of health 
economic benefits of bariatric surgery indicate an overall positive trend, largely 
via reduction of health resource utilization. To firmly establish its impact, future 
studies need to conduct head-to-head comparisons, determine optimal patient 
populations, and employ standard clinical endpoints to demonstrate real world, 
long-term benefits.
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objeCtives: Type 2-diabetes and excess weight incur large costs to health care 
systems, but the association between weight progression in diabetes and health 
care costs is unknown. We investigated those relations using real world data 
in a sample of newly diagnosed diabetes patients in Sweden by using repeated 
body mass index (BMI) measurement and health care resource utilization 
data Methods: Patients with a BMI (kg/m2) measure at diagnosis and subsequent 
BMI measures at 12,24,36,48, and 60 months were identified from a previously 
conducted register study. Individuals were classified into three groups based on 
their BMI change over 5 years: increase (> 1 BMI unit increase), decrease (> 1 BMI 
unit decrease), and stable (≤ 1 BMI unit change). Each group was stratified by BMI 
at diagnosis (BMI 18-25; 25-30; ≥ 30). Health care costs for each group were esti-
mated by applying Swedish unit costs to the health care resource data extracted 
from electronic patient journals and a national patient register. Results: The 
study included 903 T2D patients (women, 43%; mean age, 62; mean HbA1c, 6.78%; 
mean BMI, 30.9). The BMI increased, decreased, or remained stable in 178 (20%), 
387 (43%), and 338 (37%) patients, respectively. Among patients with baseline BMI 
18-25 (n= 104), the five year cumulative health care costs were € 13,695, € 9,059, 
€ 8,936, in the increase, decrease, and stable group, respectively. Corresponding 
figures were € 11,470, € 7,950, € 8,683 for patients with baseline BMI 25-30 (n= 321), 
€ 14,387, € 9,465, and € 9,302 for patients with BMI ≥ 30 (n= 478). ConClusions: In 
newly diagnosed diabetes, an increase in BMI lead to increased health care costs, 
irrespective of baseline BMI. Linking registry data on repeated BMI measurements 
and health care utilization is a valuable approach to investigate the association 
between weight changes and costs. Costs of interventions that maintain weight 
in patients with diabetes should be considered in the context of costs associated 
with weight gain.
